Efficacy and safety of first-line gefitinib treatment in metastatic lung adenocarcinoma patients with sensitizing EGFR mutation determined by ddPCR in plasma cell-free DNA (BENEFIT trial)

被引：0
|
作者：
Wang, J. [1 ]
Cheng, Y. [2 ]
Wu, Y-L. [3 ]
An, T. [4 ]
Gao, H. [5 ]
Wang, K. [6 ]
Zhou, Q. [3 ]
Hu, Y. [7 ,13 ]
Song, Y. [8 ]
Ding, C. [9 ]
Ye, X. [10 ]
Peng, F. [11 ]
Liang, L. [12 ]
Hu, Y. [7 ,13 ]
Huang, C. [14 ]
Zhou, C. [15 ]
Shi, Y-K. [16 ]
Zhang, L. [17 ]
Gu, Y. [10 ]
机构：
[1] Chinese Acad Med Sci, Canc Inst & Hosp, Internal Med, Beijing, Peoples R China
[2] Jilin Prov Canc Hosp, Med Oncol, Changchun, Peoples R China
[3] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[4] Peking Univ, Canc Hosp, Beijing Canc Hosp, Thorac Med Oncol, Beijing, Peoples R China
[5] PLA AMMS China, Hosp 307, Med Oncol, Beijing, Peoples R China
[6] Zhejiang Canc Hosp, Genet, Hangzhou, Zhejiang, Peoples R China
[7] Hubei Prov Tumor Hosp, Med Oncol, Wuhan, Peoples R China
[8] Nanjing Mil Gen Hosp, Oncol, Nanjing, Jiangsu, Peoples R China
[9] Hebei Prov Tumor Hosp, Oncol, Shijiazhuang, Peoples R China
[10] AstraZeneca, Asia & Emerging Markets iMed, Shanghai, Peoples R China
[11] Sichuan Univ, West China Hosp, Med Oncol, Chengdu, Peoples R China
[12] Beijing Univ, Hosp 3, Med Oncol, Beijing, Peoples R China
[13] Chinese Peoples Liberat Army Gen Hosp, Med Oncol, Beijing, Peoples R China
[14] Fujian Prov Canc Hosp, Med Oncol, Fuzhou, Peoples R China
[15] Tongji Univ, Tongji Hosp, Lung Canc Oncol & Immunol, Shanghai, Peoples R China
[16] Chinese Acad Med Sci, Canc Inst & Hosp, Med Oncol, Beijing, Peoples R China
[17] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.88
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1288TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [11] High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma
    Moiseyenko, Vladimir M.
    Procenko, Svetlana A.
    Levchenko, Evgeny V.
    Barchuk, Alexey S.
    Moiseyenko, Fedor V.
    Iyevleva, Aglaya G.
    Mitiushkina, Nathalia V.
    Togo, Alexandr V.
    Semionov, Igor I.
    Ivantsov, Alexandr O.
    Matsko, Dmitry E.
    Imyanitov, Evgeny N.
    ONKOLOGIE, 2010, 33 (05): : 231 - 238
  • [12] Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
    Wang, Zhijie
    Cheng, Ying
    An, Tongtong
    Gao, Hongjun
    Wang, Kai
    Zhou, Qing
    Hu, Yanping
    Song, Yong
    Ding, Cuimin
    Peng, Feng
    Liang, Li
    Hu, Yi
    Huang, Cheng
    Zhou, Caicun
    Shi, Yuankai
    Zhang, Li
    Ye, Xin
    Zhang, Meizhuo
    Chuai, Shaokun
    Zhu, Guanshan
    Hu, Jin
    Wu, Yi-long
    Wang, Jie
    LANCET RESPIRATORY MEDICINE, 2018, 6 (09): : 681 - 690
  • [13] Comparison of EGFR Mutation Status in Tissue and Plasma Cell-Free DNA Detected by ARMS in Advanced Lung Adenocarcinoma Patients
    Li, Y.
    Xu, H.
    Su, S.
    Ye, J.
    Chen, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S690 - S691
  • [14] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
    An, Chaolun
    Zhang, Jiajun
    Chu, Hongjun
    Gu, Chunyan
    Xiao, Feng
    Zhu, Fengwei
    Lu, Rujian
    Shi, Hai
    Zhang, Hongfei
    Yi, Xin
    PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
  • [15] Efficacy of EGFR-TKIs Compared with Chemotherapy as First-Line Therapy in Patients with EGFR Rare Mutation Advanced Lung Adenocarcinoma
    Wang, H.
    Li, H.
    Zhang, M.
    Zhang, G.
    Zhang, X.
    Ma, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S985 - S985
  • [16] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [17] First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).
    Shi, Yuankai
    Wang, Lin
    Han, Baohui
    Li, Wei
    Yu, Ping
    Liu, Yunpeng
    Ding, Cuimin
    Song, Xia
    Yong, Ma Zhi
    Ren, Xinling
    Feng, Ji Feng
    Zhang, Helong
    Chen, Gongyan
    Wu, Ning
    Han, Xiaohong
    Yao, Chen
    Song, Yong
    Zhang, Shucai
    Ding, Lieming
    Tan, Fenlai
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [18] ECONOMIC EVALUATION OF GEFITINIB FOR FIRST-LINE TREATMENT OF EGFR MUTATION POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS IN GREECE
    Fragoulakis, V
    Pallis, A.
    Kourlaba, G.
    Georgoulias, V
    Maniadakis, N.
    VALUE IN HEALTH, 2011, 14 (07) : A454 - A454
  • [19] A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients
    Xu, Hanyan
    Baidoo, Adam Abdul Hakeem
    Su, Shanshan
    Ye, Junru
    Chen, Chengshui
    Xie, Yupeng
    Bertolaccini, Luca
    Ismail, Mahmoud
    Ricciuti, Biagio
    Ng, Calvin Sze Hang
    Flores, Raja M.
    Li, Yuping
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (02) : 135 - +
  • [20] Sputum Cell-Free DNA Valued Surrogate Sample for Detection of EGFR Mutation in Patients with Advanced Lung Adenocarcinoma
    Wang, Zheng
    Zhang, Lin
    Li, Lin
    Li, Xiaoguang
    Xu, Yan
    Wang, Mengzhao
    Liang, Li
    Jiao, Peng
    Li, Yuanming
    He, Shurong
    Du, Jun
    He, Lei
    Tang, Min
    Sun, Mingjun
    Yang, Li
    Di, Jing
    Zhu, Guanshan
    Shi, Hong
    Liu, Dongge
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (07): : 934 - 942
12345